Vanda Pharmaceuticals Inc. and AnaptysBio Inc.
Type: License agreement
In-Licensee: Vanda Pharmaceuticals Inc.
Out-Licensor: AnaptysBio
Focus: Imsidolimab
Upfront Payment: $10 million
Milestone payments: $35 million
Financial impact: Imsidolimab is expected to have annual global revenues of approximately $22 million by 2037.
Vanda Pharmaceuticals Inc. and AnaptysBio, Inc. have entered into a global licensing agreement for developing and commercializing imsidolimab, an IL-36R antagonist monoclonal antibody. Imsidolimab has completed two global Phase 3, registration-enabling trials—GEMINI-1 and GEMINI-2—focused on assessing its safety and efficacy in patients with Generalized Pustular Psoriasis (GPP).
Under the agreement, Vanda Pharmaceutical will obtain exclusive worldwide rights to develop, manufacture, and commercialize imsidolimab. In return, Vanda Pharmaceuticals will pay AnaptysBio $10 million upfront, along with an additional $5 million for the existing drug supply. AnaptysBio is also eligible to receive up to $35 million in future milestone payments tied to regulatory approvals and sales performance, as well as a 10% royalty on net sales of the product.
Imsidolimab
Imsidolimab is a fully humanized IgG4 monoclonal antibody designed to block the activity of the interleukin-36 receptor (IL-36R) and is currently in development for the treatment of Generalized Pustular Psoriasis (GPP). The therapy is expected to benefit from regulatory and patent exclusivity extending into the late 2030s.
GPP is a rare, chronic, and potentially life-threatening systemic autoinflammatory condition. Without treatment, it can lead to severe health complications. During a flare, patients typically experience the sudden appearance of painful pustules across large areas of the skin, often accompanied by redness, intense itching, and skin that becomes dry, cracked, or scaly. In addition to these dermatologic symptoms, individuals with GPP may also suffer from systemic effects such as fever, headaches, fatigue, and a burning sensation in the skin.
Five years' market revenue of Vanda Pharmaceuticals
Vanda Pharmaceuticals has maintained a strong focus on rare diseases, with a track record of developing and commercializing therapies targeting these conditions. The company experienced steady revenue growth through 2021; however, beginning in 2022, revenues began to decline. This downturn was largely driven by the at-risk launch of generic alternatives to Vanda’s flagship product, Hetlioz. The impact of generics continued to weigh on revenue in both 2023 and 2024.
Five years market revenue of Vanda Pharmaceuticals (2020-2024)
Fig 9: Market revenue of Vanda Pharmaceuticals
Despite these challenges, the acquisition of PONVORY in December 2023 helped partially offset revenue losses, adding a new asset to Vanda Pharmaceutical’s portfolio. Looking ahead, Vanda Pharmaceutical’s recent partnership with AnaptysBio, Inc. is expected to support a return to revenue growth. Through this agreement, Vanda Pharmaceutical has secured exclusive global rights to develop and commercialize imsidolimab, a potential first-in-class treatment for Generalized Pustular Psoriasis (GPP). The collaboration leverages Vanda Pharmaceutical’s robust regulatory and commercial infrastructure along with AnaptysBio’s immunotherapy development expertise, positioning imsidolimab for potential success and contributing to Vanda Pharmaceutical’s future financial recovery and growth.
Market Impact of This Partnership
The Generalized Pustular Psoriasis (GPP) market is projected to reach USD 36.9 billion by 2035, driven by significant advancements in targeted biologic therapies. This growth reflects rising awareness, improved diagnostic rates, and increasing adoption of innovative treatments aimed at addressing the high unmet needs in GPP management.
Among the emerging therapies, imsidolimab—an IL-36R antagonist monoclonal antibody—shows strong commercial potential. Imsidolimab is expected to generate annual global revenues of approximately $22 million by 2037. These revenue projections, combined with estimated development and commercialization costs, are used to calculate the drug’s net present value (NPV)—a key financial metric for evaluating its investment viability.
As the GPP market continues to expand, imsidolimab is well-positioned to capture market share as a potentially first-in-class therapy offering a targeted mechanism of action for this rare and severe dermatologic condition.